Quest Diagnostics reported a strong third quarter with an 8.5% increase in total revenue, including 4.2% organic growth. The company's performance was driven by new customer wins, expanded business with physicians and hospitals, and recent acquisitions. Due to contributions from recent acquisitions, the company has increased its 2024 revenue guidance and has maintained the midpoint of its adjusted EPS guidance despite the impact of Hurricane Milton in the fourth quarter.
Third quarter revenues increased by 8.5% compared to 2023.
Reported diluted earnings per share increased by 1.5% from 2023.
Adjusted diluted earnings per share increased by 3.6% from 2023.
Full year 2024 revenues are now expected to be between $9.80 billion and $9.85 billion.
The company updates its full year 2024 guidance. The updated guidance reflects the impact of recent acquisitions including LifeLabs as well as the impact from Hurricane Milton in the fourth quarter. The company projects the disruption from Hurricane Milton to negatively impact net revenues by approximately $15 million and EPS by approximately 8 cents in the fourth quarter.